208 related articles for article (PubMed ID: 11494132)
1. An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2.
Evans SC; Viswanathan M; Grier JD; Narayana M; El-Naggar AK; Lozano G
Oncogene; 2001 Jul; 20(30):4041-9. PubMed ID: 11494132
[TBL] [Abstract][Full Text] [Related]
2. Regulation of hdm2 by stress-induced hdm2alt1 in tumor and nontumorigenic cell lines correlating with p53 stability.
Dias CS; Liu Y; Yau A; Westrick L; Evans SC
Cancer Res; 2006 Oct; 66(19):9467-73. PubMed ID: 17018602
[TBL] [Abstract][Full Text] [Related]
3. Abundant expression of spliced HDM2 in Hodgkin lymphoma cells does not interfere with p14(ARF) and p53 binding.
Stürzenhofecker B; Schlott T; Quentin T; Kube D; Jung W; Trümper L
Leuk Lymphoma; 2003 Sep; 44(9):1587-96. PubMed ID: 14565663
[TBL] [Abstract][Full Text] [Related]
4. Hodgkin's lymphoma cells express alternatively spliced forms of HDM2 with multiple effects on cell cycle control.
Sánchez-Aguilera A; García JF; Sánchez-Beato M; Piris MA
Oncogene; 2006 Apr; 25(18):2565-74. PubMed ID: 16331255
[TBL] [Abstract][Full Text] [Related]
5. Identification of an aberrantly spliced form of HDMX in human tumors: a new mechanism for HDM2 stabilization.
Giglio S; Mancini F; Gentiletti F; Sparaco G; Felicioni L; Barassi F; Martella C; Prodosmo A; Iacovelli S; Buttitta F; Farsetti A; Soddu S; Marchetti A; Sacchi A; Pontecorvi A; Moretti F
Cancer Res; 2005 Nov; 65(21):9687-94. PubMed ID: 16266988
[TBL] [Abstract][Full Text] [Related]
6. Nucleolar p14(ARF) overexpression in Reed-Sternberg cells in Hodgkin's lymphoma: absence of p14(ARF)/Hdm2 complexes is associated with expression of alternatively spliced Hdm2 transcripts.
García JF; Villuendas R; Sánchez-Beato M; Sánchez-Aguilera A; Sánchez L; Prieto I; Piris MA
Am J Pathol; 2002 Feb; 160(2):569-78. PubMed ID: 11839577
[TBL] [Abstract][Full Text] [Related]
7. p53-independent activation of the hdm2-P2 promoter through multiple transcription factor response elements results in elevated hdm2 expression in estrogen receptor alpha-positive breast cancer cells.
Phelps M; Darley M; Primrose JN; Blaydes JP
Cancer Res; 2003 May; 63(10):2616-23. PubMed ID: 12750288
[TBL] [Abstract][Full Text] [Related]
8. Alternative and aberrant messenger RNA splicing of the mdm2 oncogene in invasive breast cancer.
Lukas J; Gao DQ; Keshmeshian M; Wen WH; Tsao-Wei D; Rosenberg S; Press MF
Cancer Res; 2001 Apr; 61(7):3212-9. PubMed ID: 11306511
[TBL] [Abstract][Full Text] [Related]
9. Genetic alterations of the p14ARF -hdm2-p53 regulatory pathway in breast carcinoma.
Ho GH; Calvano JE; Bisogna M; Abouezzi Z; Borgen PI; Cordón-Cardó C; van Zee KJ
Breast Cancer Res Treat; 2001 Feb; 65(3):225-32. PubMed ID: 11336244
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of Mdm2 and MdmX fusion proteins alters p53 mediated transactivation, ubiquitination, and degradation.
Ghosh M; Huang K; Berberich SJ
Biochemistry; 2003 Mar; 42(8):2291-9. PubMed ID: 12600196
[TBL] [Abstract][Full Text] [Related]
11. p53 apoptotic pathway molecules are frequently and simultaneously altered in nonsmall cell lung carcinoma.
Mori S; Ito G; Usami N; Yoshioka H; Ueda Y; Kodama Y; Takahashi M; Fong KM; Shimokata K; Sekido Y
Cancer; 2004 Apr; 100(8):1673-82. PubMed ID: 15073856
[TBL] [Abstract][Full Text] [Related]
12. Genotoxic stress induces coordinately regulated alternative splicing of the p53 modulators MDM2 and MDM4.
Chandler DS; Singh RK; Caldwell LC; Bitler JL; Lozano G
Cancer Res; 2006 Oct; 66(19):9502-8. PubMed ID: 17018606
[TBL] [Abstract][Full Text] [Related]
13. MEK-ERK signaling controls Hdm2 oncoprotein expression by regulating hdm2 mRNA export to the cytoplasm.
Phelps M; Phillips A; Darley M; Blaydes JP
J Biol Chem; 2005 Apr; 280(17):16651-8. PubMed ID: 15723837
[TBL] [Abstract][Full Text] [Related]
14. Expression of alternatively spliced mdm2 transcripts correlates with stabilized wild-type p53 protein in human glioblastoma cells.
Kraus A; Neff F; Behn M; Schuermann M; Muenkel K; Schlegel J
Int J Cancer; 1999 Mar; 80(6):930-4. PubMed ID: 10074928
[TBL] [Abstract][Full Text] [Related]
15. Analysis of the molecular species generated by MDM2 gene amplification in liposarcomas.
Tamborini E; Della Torre G; Lavarino C; Azzarelli A; Carpinelli P; Pierotti MA; Pilotti S
Int J Cancer; 2001 Jun; 92(6):790-6. PubMed ID: 11351297
[TBL] [Abstract][Full Text] [Related]
16. Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein.
Roth J; Dobbelstein M; Freedman DA; Shenk T; Levine AJ
EMBO J; 1998 Jan; 17(2):554-64. PubMed ID: 9430646
[TBL] [Abstract][Full Text] [Related]
17. A comparative study of P53/MDM2 genes alterations and P53/MDM2 proteins immunoreactivity in soft-tissue sarcomas.
Rieske P; Bartkowiak JK; Szadowska AM; Olborski B; Harezga-Bal B; Debiec-Rychter M
J Exp Clin Cancer Res; 1999 Sep; 18(3):403-16. PubMed ID: 10606188
[TBL] [Abstract][Full Text] [Related]
18. Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53.
Tao W; Levine AJ
Proc Natl Acad Sci U S A; 1999 Mar; 96(6):3077-80. PubMed ID: 10077639
[TBL] [Abstract][Full Text] [Related]
19. An intact HDM2 RING-finger domain is required for nuclear exclusion of p53.
Boyd SD; Tsai KY; Jacks T
Nat Cell Biol; 2000 Sep; 2(9):563-8. PubMed ID: 10980695
[TBL] [Abstract][Full Text] [Related]
20. A small nuclear RNA, hdm365, is the major processing product of the human mdm2 gene.
Bartl S; Ban J; Weninger H; Jug G; Kovar H
Nucleic Acids Res; 2003 Feb; 31(4):1136-47. PubMed ID: 12582232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
